Diabetes BOOST Program for Type 2 Diabetes

Recruiting at 1 trial location

Overseen By Geraldine Puerto, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Daniel Amante

Disqualifiers: Cognitive impairment, Pregnant, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

70 Participants Needed

Trial Summary

What is the purpose of this trial?

The specific aims of this project are to culturally adapt the DM-BOOST intervention for Latinx patients, usability test 'DM-BOOST para Latinx' to optimize cultural appropriateness and patient engagement and conduct a feasibility evaluation of DM-BOOST para Latinx. These aims will be accomplished via a community-based participatory research approach in collaboration with clinical, community and patient partners. This project will inform subsequent proposals to evaluate implementation of DM-BOOST in the UMass Memorial Health Care system.

Research Team

Daniel Amante, PhD, MPH

Principal Investigator

UMass Chan Medical School

Eligibility Criteria

This trial is for Hispanic/Latinx adults over 18 with type 2 diabetes who prefer to speak Spanish and have completed a diabetes self-management training in the past year. It's not suitable for those with cognitive impairments, pregnant women, or current prisoners.

Inclusion Criteria

I am older than 18 years.

I have been diagnosed with type 2 diabetes.

I completed a diabetes self-management training last year.

Exclusion Criteria

Pregnant women

Current prisoner

I have difficulty with memory or thinking clearly.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants complete a baseline survey, receive DSMT referral, and engage in self-care education via secure messages, text messages, and video calls. They also complete a telehealth training video call and set personalized goals.

3 months

Multiple virtual interactions

Follow-up

Participants complete a 3-month follow-up survey and qualitative interview to assess diabetes treatment satisfaction and self-efficacy.

3 months

Extended Follow-up

Participants' HbA1c values are monitored to determine the impact of the intervention, with data obtained through EHR chart review.

6 months

Treatment Details

Interventions

• Diabetes BOOST
• Usual Care

Trial Overview The study is testing 'DM-BOOST para Latinx,' an adapted version of the DM-BOOST program designed to help Latinx patients manage their diabetes using behavioral economics and technology. The effectiveness will be assessed through community-based participatory research.

Participant Groups

Group I: Intervention - Diabetes BOOST Experimental Treatment 1 Intervention

Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff to review the functionality of their patient portal and refine diabetes-related goals. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.

Group II: Usual Care Active Control 1 Intervention

Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.

Who Is Running the Clinical Trial?

Daniel Amante

Lead Sponsor

Trials

2

Recruited

140+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials

2,513

Recruited

4,366,000+